EP1311202A1 - Procede et systeme de revision de dose d'anticoagulant - Google Patents

Procede et systeme de revision de dose d'anticoagulant

Info

Publication number
EP1311202A1
EP1311202A1 EP01963959A EP01963959A EP1311202A1 EP 1311202 A1 EP1311202 A1 EP 1311202A1 EP 01963959 A EP01963959 A EP 01963959A EP 01963959 A EP01963959 A EP 01963959A EP 1311202 A1 EP1311202 A1 EP 1311202A1
Authority
EP
European Patent Office
Prior art keywords
dose
patient
warfarin
response
current
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01963959A
Other languages
German (de)
English (en)
Other versions
EP1311202A4 (fr
Inventor
John D. Kutzko
Michaeal G. Singer
John Mcmichael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimensional Dosing Systems Inc
Original Assignee
RxFiles Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/644,503 external-priority patent/US6942614B1/en
Application filed by RxFiles Corp filed Critical RxFiles Corp
Priority claimed from CA002401913A external-priority patent/CA2401913A1/fr
Publication of EP1311202A1 publication Critical patent/EP1311202A1/fr
Publication of EP1311202A4 publication Critical patent/EP1311202A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention relates generally to a method and system for use in treating a patient with an anticoagulant to optimize drug therapy and to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin.
  • the present invention can utilize either drug levels or other surrogate markers to determine the effectiveness of the dosing regimen and, if necessary, to suggest a new more optimal drug dose.
  • anticoagulant includes, but is not limited to, warfarin, Coumadin®, heparin, warfarin sodium salt, coumarin derivatives, indandione derivatives, dicumarol, anisindione, phenindione, ethyl bicoumacetate, bishydroxycoumarin, abcimixab, Reopro®, actilyse, alteplase, Activase®, anagrelide, Agrylin®, anistreplase, Eminase®, antithrombin III, Thrombate III®, ardeparin, Normiflo®, argatroban, clopidrogel, Plavix®, dalteparin, Fragmin®, danaparoid, Orgaran®, dipyridamole, Persantine®, dipyridamole/aspirin, Aggrenox®, duteplase, enoxaparin, Lovenox®, eptifi
  • anticoagulant is also intended to mean species which employ any or more of the individual anticoagulants as defined and/or alluded to hereinabove.
  • BACKGROUND OF THE INVENTION When a patient begins taking an anticoagulant or any medication for a length of time, a titration of the amount of drug taken by the patient is necessary in order to achieve the optimal benefit of the drug, and at the same time to prevent any undesirable side effects that taking too much of the drug could produce. Thus, there is a continuous balance between taking enough drug in order to gain the benefits from that drug and at the same time not taking so much drug as to illicit a toxic event.
  • Bayesian analysis is another method used to relate drug dose to efficacy. This method employs large-scale population parameters to stratify a population in order to better characterize the individuals. This method does not take into account the changes that can occur within a person over time, and as a result cannot reliably estimate dosages.
  • Pharmacokinetic compartment modeling has had success with some drugs, but because the models are static and cannot adapt themselves to changes within a population or a patient, they are once again undesirable for dynamically determining drug dosages.
  • patient dosing occurs through a cyclic series of events, depicted in flow chart form in Figure 1.
  • a drug such as an anticoagulant
  • the initial dose is based on the FDA recommended dosage found on the drug label.
  • the anticoagulant dose is further refined upon repeated dosing by the physician based on the patient's response to the anticoagulant. Too much anticoagulant could cause the patient to experience toxic anticoagulant effects, and the anticoagulant dose would need to be reduced. Too little anticoagulant could cause the patient not to receive the benefit the anticoagulant therapy could offer, and the dosage would need to be increased.
  • the preferred embodiment of the invention requires that a physician determine the percentage of response by the patient to the anticoagulant based on the surrogate markers for that anticoagulant. A relationship is then employed which uses the input parameters described above to determine the next dose for the patient.
  • the invention also includes embodiments focused on specific anticoagulants, such as, for example only, Coumadin®, warfarin, substances containing warfarin, etc.
  • the invention includes a method for calculating a revised dose of Coumadin® for a patient using Coumadin®, comprising the steps of: accepting as a first input the patient's current Coumadin® dose; accepting as a second input a maximum dose of Coumadin®; accepting as a third input a percent response of the patient based on one or more surrogate markers for said patient; and determining a revised dose, wherein said revised dose is a function of said current dose minus a ratio of the percent response of the patient and a ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
  • Another example is a method for determining a dose of warfarin or a substance containing warfarin for a patient, comprising the steps of: administering an initial dose of Warfarin or said substance containing warfarin to the patient; examining the patient to monitor and characterize one or more numerical surrogate markers; determining if a dose change is necessary; and calculating a revised dose as a function of said current dose minus the ratio of the change in numerical markers and the ratio of said current dose to said maximum dose plus the percent of individual patient response multiplied by a response factor.
  • Each specie of the invention has two preferred embodiments; one which uses actual numerical surrogate markers to calculate a dose, and another embodiment that uses percentages as the numerical input for the surrogate markers.
  • Figure 1 shows a flow chart of the process by which revised doses of an anticoagulant are determined, according to the method of the invention described herein.
  • Figure 2 shows an apparatus for use in calculating revised doses of an anticoagulant according to the present invention.
  • the present invention provides a method and system for use in treating a patient receiving an anticoagulant or a substance containing warfarin to optimize therapy and to prevent an adverse drug response.
  • This system employs surrogate markers or indicators including blood levels of the anticoagulant to determine the next required dose for a patient. Because the surrogate markers are employed as a percent change in status, virtually any indicator can be used. Surrogate markers could include any measure of the effectiveness of the anticoagulant's action. Given the effectiveness of the anticoagulant's action relative to the surrogate markers, a change in anticoagulant dose is calculated by the system. Conversely, by employing this system, one could determine the expected result of the anticoagulant dose change on the surrogate markers.
  • FIG. 1 shows a flow chart of the overall process of treating a patient using this expert system.
  • the actual expert system performs only the steps shown in blocks 10 and 12 of the flow chart.
  • This expert system includes a general purpose computer, shown in Figure 2, comprising an input means, preferably a keyboard 20 and/or a mouse 22, an output means 30, preferably a video display screen, a data storage means 50, preferably a hard disk drive, and a processor.
  • the expert computer program receives input data from a physician regarding the patient's current anticoagulant dose, the maximal dose range for the anticoagulant, and the percent response of the patient based on the surrogate markers used to monitor the anticoagulant. Also characterized is the patient's response to the last dosing cycle as well as a dose response constant. This allows the expert system to individualize the patient dosing based on the patient's individual response to the anticoagulant.
  • the system calculates a revised dosage based on the data input by the physician.
  • the software portion of the invention includes a user interface portion 100 to receive the input data and to output the revised dosage information, and a data analysis portion 110, which calculates the new dosage information based on the input data.
  • a physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant.
  • the physician then re- evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed.
  • the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant.
  • the numerical markers will evaluated to see if the desired effect of the anticoagulant is being achieved. Based on this evaluation by the physician, the current anticoagulant dose, the current anticoagulant numerical marker, the desired anticoagulant numerical marker, and the previous anticoagulant numerical marker are then input into the embodiment and the new anticoagulant dose is calculated based on the equation:
  • NAD CAD - ⁇ [ ⁇ (CANM - DANM)/CANM)/(1+ (CAD/HIGH))] x CAD ⁇ + LV
  • LV ⁇ (RESP x CAD) x [(1+D) - (1+E)]/ abs (1+D) ⁇ / [1.3 ⁇ (CAD/HIGH)]
  • CANM Current Anticoagulant Numerical Marker
  • DANM Desired Anticoagulant Numerical Marker
  • PANM Previous Anticoagulant Numerical Marker
  • a physician prescribes an anticoagulant for a patient based on the FDA recommended dose on the label of the anticoagulant.
  • the physician then re-evaluates the patient, usually daily, either in person or remotely depending on the agent being prescribed.
  • the surrogate markers are monitored and sequentially compared to determine if there are any toxicities associated with the anticoagulant. Also the surrogate markers are evaluated to see if the desired effect of the anticoagulant is being achieved.
  • NAD CAD - ⁇ [((PAR - 100)/PAR)/(1+ (CAD/HIGH))] x CAD ⁇ + LV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé et un système utiles dans le traitement d'un patient recevant un anticoagulant ou un produit contenant de la warfarine, et visant à optimiser le traitement et à prévenir une réaction indésirable à un médicament. Le système comporte les étapes représentées dans les blocs (10, 12) du diagramme. Ce système emploie des critères ou indicateurs de substitution incluant les taux sanguins de l'anticoagulant afin de déterminer la dose suivante requise pour un patient. Comme on emploie les critères de substitution comme différence en pour cent de l'état du patient, pratiquement n'importe quel indicateur peut être utilisé. Les critères de substitution peuvent inclure n'importe quelle mesure de l'efficacité d'un anticoagulant. Selon l'efficacité mesurée de l'anticoagulant par rapport aux critères de substitution, une modification de la dose d'anticoagulant est calculée par le système. Inversement, ce système permet de déterminer le résultat prévu de la modification de la dose d'anticoagulant sur les critères de substitution.
EP01963959A 2000-08-24 2001-08-13 Procede et systeme de revision de dose d'anticoagulant Ceased EP1311202A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/644,503 US6942614B1 (en) 1999-07-06 2000-08-24 Method and system for use in treating a patient with an anticoagulant to optimize therapy and prevent an adverse drug response
US644503 2000-08-24
PCT/US2001/025362 WO2002019935A1 (fr) 2000-08-24 2001-08-13 Procede et systeme de revision de dose d'anticoagulant
CA002401913A CA2401913A1 (fr) 1999-07-06 2002-09-06 Methode, dispositif et systeme pour utilisation dans le traitement d'un patient par un medicament antineoplasique pour optimiser la therapie et prevenir une reaction indesirable au medicament

Publications (2)

Publication Number Publication Date
EP1311202A1 true EP1311202A1 (fr) 2003-05-21
EP1311202A4 EP1311202A4 (fr) 2007-04-18

Family

ID=32928334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01963959A Ceased EP1311202A4 (fr) 2000-08-24 2001-08-13 Procede et systeme de revision de dose d'anticoagulant

Country Status (3)

Country Link
EP (1) EP1311202A4 (fr)
AU (1) AU2001284868A1 (fr)
WO (1) WO2002019935A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058373A2 (fr) * 2003-12-12 2005-06-30 Petra Biotek, Inc. Procedes, progiciel, et systemes posologique a agent simple et a agents multiples et autres procedes connexes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002050A2 (fr) * 1999-07-06 2001-01-11 The Rxfiles Corporation Technique et systeme utilise pour traiter un patient avec un medicament, afin d'optimiser une therapie et d'empecher un effet secondaire de ce medicament

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5694950A (en) * 1992-08-21 1997-12-09 J & W Mcmichael Software, Inc. Method and system for use in treating a patient with immunosuppresants using whole blood level criteria to prevent an adverse immune response
US5365948A (en) * 1992-08-21 1994-11-22 J & W Mcmichael Software Inc. Method for use in treating a patient with FK 506 to prevent an adverse immune response

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001002050A2 (fr) * 1999-07-06 2001-01-11 The Rxfiles Corporation Technique et systeme utilise pour traiter un patient avec un medicament, afin d'optimiser une therapie et d'empecher un effet secondaire de ce medicament

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANSELL J ET AL: "Managing oral anticoagulant therapy." CHEST JAN 2001, vol. 119, no. 1 Suppl, January 2001 (2001-01), pages 22S-38S, XP002419348 ISSN: 0012-3692 *
POLLER ET AL: "Multicentre randomised study of computerised anticoagluant dosage" THE LANCET, vol. 352, pages 1505-1509, XP004265723 *
See also references of WO0219935A1 *

Also Published As

Publication number Publication date
EP1311202A4 (fr) 2007-04-18
AU2001284868A1 (en) 2002-03-22
WO2002019935A1 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
US6942614B1 (en) Method and system for use in treating a patient with an anticoagulant to optimize therapy and prevent an adverse drug response
Willmann et al. Integrated population pharmacokinetic analysis of rivaroxaban across multiple patient populations
Soares et al. A mixture model for water uptake, degradation, erosion and drug release from polydisperse polymeric networks
Wallin et al. Model‐based neutrophil‐guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information
Cella et al. A model‐based approach to dose selection in early pediatric development
US20160279329A1 (en) System and method for drug delivery
EP1612708A1 (fr) Système d'analyse d'essai clinique et simulateur d'essai cliniques pour essais des médicaments
Deal et al. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series
Cote et al. Persistent pulmonary embolism rates following total knee arthroplasty even with prophylactic anticoagulants
US6575169B2 (en) Method and apparatus for use in treating a patient with any drug to optimize therapy and prevent an adverse drug
Mazzocco et al. Prediction of response to temozolomide in low‐grade glioma patients based on tumor size dynamics and genetic characteristics
CA3142237A1 (fr) Procede de determination d'un schema posologique optimal de medicament
Baron et al. Missing data in randomized controlled trials of rheumatoid arthritis with radiographic outcomes: a simulation study
Kakara et al. Population pharmacodynamic analysis of LDL‐cholesterol lowering effects by statins and co‐medications based on electronic medical records
EP1311202A1 (fr) Procede et systeme de revision de dose d'anticoagulant
WO2008118817A3 (fr) Systèmes et procédés pour améliorer l'évaluation et la déclaration de l'efficacité et de l'innocuité de traitements médicamenteux, biologiques, botaniques, par des vitamines, par une alimentation médicale et des dispositifs médicaux
CA2419431A1 (fr) Procede et systeme de revision de dose d'anticoagulant
Barras et al. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations
Kumar et al. The effect of decontamination procedures on the pharmacokinetics of venlafaxine in overdose
Delavenne et al. Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery
Sahlén et al. Direct oral anticoagulation versus warfarin in left ventricular thrombus: pooled analysis of randomized controlled trials
Imperiale et al. Measuring the hemodynamic response to primary pharmacoprophylaxis of variceal bleeding: a cost-effectiveness analysis
Baker et al. Inference for meta‐analysis with a suspected temporal trend
Scott et al. Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients
Nielsen et al. Population dose‐response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030227

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DIMENSIONAL DOSING SYSTEMS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/02 20060101ALI20070302BHEP

Ipc: A61K 31/00 20060101AFI20070302BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070315

17Q First examination report despatched

Effective date: 20070514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20081015